StockData
Lifecore Biomedical, Inc. logo

Lifecore Biomedical, Inc. (LFCR) income statement

LFCRNasdaqPharmaceutical PreparationsFiscal year ends May 25
Số liệu tài chính tới Q4 năm tài chính 2025, quý kết thúc ngày May 25, 2025Last filing: 10-Q on Nov 4, 2026Score 4/30
$6.40+0.01 (+0.16%)

Close on Nov 18, 2026Market cap $242.26MP/E –Yield –

Lifecore Biomedical, Inc. income statement

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin
31.3%
Operating margin
-13.4%
Net margin
-30.0%
Return on equity, FY2025
-612.1%

Financial strength

Current ratio
3.87
Debt to equity
–
Debt to assets
–
Cash to current liabilities
79.7%

Valuation

P/E ratio
–
Price to sales
1.88
Price to book
–
Dividend yield
–

See a number that looks wrong?